Sigrid Therapeutics, a Swedish healthtech company specializing in the prevention and treatment of type-2 diabetes and obesity, today announced that the European Patent Office has granted the company patent EP2916852 titled “A porous silica material for use as a pharmaceutical or dietary active ingredient”. The patent supports use of Sigrid’s breakthrough, mesoporous silica particles (MSP)-based device which consists of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in the gut as a pharmaceutical and dietary active ingredient. Covering the EU, UK, Switzerland, Norway, Iceland and Turkey, the European patent follows similar grants in the US, Canada, Australia, Japan and Israel and significantly strengthens Sigrid’s IP portfolio.

First-in-Class Medical Device SiPore15® - based therapy significantly reduced long-term blood sugar levels and improved metabolic parameters in prediabetics.

Amidst fierce competition from other stars of Sweden’s booming start-up scene, Sana Alajmovic, founder and CEO of healthtech company Sigrid Therapeutics, was voted the winner of the Female Founders competition 2021 as voted for by readers of leading industry publication Dagens Industri.

Targeting $10 billion prediabetes/obesity market with unique fat/carbohydrate uptake reducing product

Stockholm, Sweden July 1, 2020. Sigrid Therapeutics, a Swedish clinical-stage technology company specializing in the prevention of type-2 diabetes and obesity, today announced that the Company has been granted a US patent by the United States Patent and Trademark Office (USPTO). The patent covers the use of the Company’s breakthrough, mesoporous silica particles (MSP)-based device SiPore15® for lowering of body fat, prevention and treatment of obesity. The patent (US 10,695,294) provides exclusive rights to the exploitation of the Company’s lead product in the US until 2033. 

Sigrid Therapeutics Reports Significant Blood Sugar Reduction with Excellent Safety Profile in STAR Trial with Breakthrough Medical Device SiPore15 in Prediabetes and Untreated Type 2 Diabetes